Erratum: Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in Plasma (Clin. Pharm. Ther. (2011) 89 (708-717) DOI:10.1038/clpt.2011.27);Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase i and II enzymes on their concentration levels in plasma

Clinical Pharmacology and Therapeutics

Volumn 89, Issue 5, 2011, Pages 708-717

  Murdter T E ^a,b   Schroth, W ^a,b   Bacchus Gerybadze, L ^a,b,c   Winter, S ^a,b   Heinkele, G ^a,b   Simon, W ^c   Fasching, P A ^d,e   Fehm, T ^f   Eichelbaum, M ^a,b   Schwab, M ^a,b,f   Brauch, H ^a,b  

^a DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c ROBERT BOSCH HOSPITAL   (Germany)

^d UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AFIMOXIFENE; CYTOCHROME P450 2D6; DRUG METABOLITE; ENDOXIFEN; ENZYME; ESTROGEN RECEPTOR; GLUCURONIDE; TAMOXIFEN; TAMOXIFEN DERIVATIVE; UNCLASSIFIED DRUG; BILIRUBIN GLUCURONOSIDE GLUCURONOSYLTRANSFERASE; CYP2C19 PROTEIN, HUMAN; CYTOCHROME P450; GLUCURONOSYLTRANSFERASE; UNSPECIFIC MONOOXYGENASE;

ADULT; ARTICLE; BREAST CANCER; CANCER PATIENT; CYP2B6 GENE; CYP2C19 GENE; CYP2C9 GENE; CYP2D6 GENE; CYP3A5 GENE; DRUG BLOOD LEVEL; ESTROGEN RESPONSIVE ELEMENT; FEMALE; GENE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; IC 50; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RECEPTOR DOWN REGULATION; STEADY STATE; TANDEM MASS SPECTROMETRY; UGT1A4 GENE; UGT2B15 GENE; UGT2B7 GENE; AGED; BLOOD; CHEMISTRY; CLINICAL TRIAL; COMPARATIVE STUDY; FOLLOW UP; GENETICS; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; FOLLOW-UP STUDIES; GLUCURONOSYLTRANSFERASE; HUMANS; MIDDLE AGED; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; RECEPTORS, ESTROGEN; TAMOXIFEN;

EID: 79955480679     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2012.33     Document Type: Erratum

References (46)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365, 1687-1717 (2005).
2. Jordan, V.C., Collins, M.M., Rowsby, L. & Prestwich, G. A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. J. Endocrinol. 75, 305-316 (1977). (Pubitemid 8219148)
3. Lien, E.A., Solheim, E., Kvinnsland, S. & Ueland, P.M. Identification of 4-hydroxy- N-desmethyltamoxifen as a metabolite of tamoxifen in human bile. Cancer Res. 48, 2304-2308 (1988).
4. Buck, M.B., Coller, J.K., Mürdter, T.E., Eichelbaum, M. & Knabbe, C. TGFβ2 and TβRII are valid molecular biomarkers for the antiproliferative effects of tamoxifen and tamoxifen metabolites in breast cancer cells. Breast Cancer Res. Treat. 107, 15-24 (2008). (Pubitemid 350179587)
5. Johnson, M.D. et al. Pharmacological characterization of 4-hydroxy-Ndesmethyl tamoxifen, A novel active metabolite of tamoxifen. Breast Cancer Res. Treat. 85, 151-159 (2004). (Pubitemid 38987269)
6. Lim, Y.C. et al. Endoxifen, A secondary metabolite of tamoxifen, And 4-OHtamoxifen induce similar changes in global gene expression patterns in MCF- 7 breast cancer cells. J. Pharmacol. Exp. Ther. 318, 503-512 (2006).
7. Jin, Y. et al. CYP2D6 genotype, Antidepressant use, And tamoxifen metabolism during adjuvant breast cancer treatment. J. Natl. Cancer Inst. 97, 30-39 (2005).
8. Lim, H.S., Ju Lee, H., Seok Lee, K., Sook Lee, E., Jang, I.J. & Ro, J. Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer. J. Clin. Oncol. 25, 3837-3845 (2007). (Pubitemid 47477258)
9. Lim, C.K., Yuan, Z.X., Lamb, J.H., White, I.N., De Matteis, F. & Smith, L.L. A comparative study of tamoxifen metabolism in female rat, Mouse and human liver microsomes. Carcinogenesis 15, 589-593 (1994). (Pubitemid 24124398)
10. Crewe, H.K., Notley, L.M., Wunsch, R.M., Lennard, M.S. & Gillam, E.M. Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4-α-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab. Dispos. 30, 869-874 (2002). (Pubitemid 34815415)
11. Coller, J.K. et al. The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver. Br. J. Clin. Pharmacol. 54, 157-167 (2002). (Pubitemid 35024939)
12. Gjerde, J., Kisanga, E.R., Hauglid, M., Holm, P.I., Mellgren, G. & Lien, E.A. Identification and quantification of tamoxifen and four metabolites in serum by liquid chromatography-tandem mass spectrometry. J. Chromatogr. A 1082, 6-14 (2005). (Pubitemid 40848583)
13. Fried, K.M. & Wainer, I.W. Direct determination of tamoxifen and its four major metabolites in plasma using coupled column high-performance liquid chromatography. J. Chromatogr. B, Biomed. Appl. 655, 261-268 (1994). (Pubitemid 24169259)
14. Lee, K.H., Ward, B.A., Desta, Z., Flockhart, D.A. & Jones, D.R. Quantification of tamoxifen and three metabolites in plasma by high-performance liquid chromatography with fluorescence detection: application to a clinical trial. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 791, 245-253 (2003). (Pubitemid 36638757)
15. Merle, O., Guitton, J., Burke, M.D., Ollangnier, M. Rapid and simple method to determine tamoxifen and its major metabolites in human liver microsomes by high performance liquid chromatography with fluorescence detection. Anal. Lett. 31, 2067-2076 (1998). (Pubitemid 28407868)
16. Milano, G. et al. Optimised analysis of tamoxifen and its main metabolites in the plasma and cytosol of mammary tumours. Br. J. Cancer 55, 509-512 (1987). (Pubitemid 17098857)
17. Katzenellenbogen, B.S., Norman, M.J., Eckert, R.L., Peltz, S.W. & Mangel, W.F. Bioactivities, Estrogen receptor interactions, And plasminogen activatorinducing activities of tamoxifen and hydroxy-tamoxifen isomers in MCF-7 human breast cancer cells. Cancer Res. 44, 112-119 (1984). (Pubitemid 14178070)
18. Osborne, C.K., Coronado, E., Allred, D.C., Wiebe, V. & DeGregorio, M. Acquired tamoxifen resistance: correlation with reduced breast tumor levels of tamoxifen and isomerization of trans-4-hydroxytamoxifen. J. Natl. Cancer Inst. 83, 1477-1482 (1991).
19. Osborne, C.K., Wiebe, V.J., McGuire, W.L., Ciocca, D.R. & DeGregorio, M.W. Tamoxifen and the isomers of 4-hydroxytamoxifen in tamoxifen-resistant tumors from breast cancer patients. J. Clin. Oncol. 10, 304-310 (1992).
20. Sun, D., Chen, G., Dellinger, R.W., Duncan, K., Fang, J.L. & Lazarus, P. Characterization of tamoxifen and 4-hydroxytamoxifen glucuronidation by human UGT1A4 variants. Breast Cancer Res. 8, R50 (2006).
21. Jaremko, M., Kasai, Y., Barginear, M.F., Raptis, G., Desnick, R.J. & Yu, C. Tamoxifen metabolite isomer separation and quantification by liquid chromatographytandem mass spectrometry. Anal. Chem. 82, 10186-10193 (2010).
22. Borges, S. et al. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin. Pharmacol. Ther. 80, 61-74 (2006). (Pubitemid 43946844)
23. Stearns, V. et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J. Natl. Cancer Inst. 95, 1758-1764 (2003). (Pubitemid 38008898)
24. Allen, K.E., Clark, E.R. & Jordan, V.C. Evidence for the metabolic activation of non-steroidal antioestrogens: a study of structure-activity relationships. Br. J. Pharmacol. 71, 83-91 (1980). (Pubitemid 11167766)
25. Coezy, E., Borgna, J.L. & Rochefort, H. Tamoxifen and metabolites in MCF7 cells: correlation between binding to estrogen receptor and inhibition of cell growth. Cancer Res. 42, 317-323 (1982). (Pubitemid 12207285)
26. Lien, E.A., Solheim, E., Lea, O.A., Lundgren, S., Kvinnsland, S. & Ueland, P.M. Distribution of 4-hydroxy-N-desmethyltamoxifen and other tamoxifen metabolites in human biological fluids during tamoxifen treatment. Cancer Res. 49, 2175-2183 (1989). (Pubitemid 19106533)
27. Wu, A.H. et al. Tamoxifen, Soy, And lifestyle factors in Asian American women with breast cancer. J. Clin. Oncol. 25, 3024-3030 (2007). (Pubitemid 47218048)
28. Kiyotani, K. et al. Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. J. Clin. Oncol. 28, 1287-1293 (2010).
29. Gjerde, J. et al. Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism. Ann. Oncol. 19, 56-61 (2008).
30. Gjerde, J. et al. Associations between tamoxifen, Estrogens, And FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer. BMC Cancer 10, 313 (2010).
31. Lim, H.S., Ju Lee, H., Seok Lee, K., Sook Lee, E., Jang, I.J. & Ro, J. Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer. J. Clin. Oncol. 25, 3837-3845.
32. Goetz, M.P. et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res. Treat. 101, 113-121 (2007). (Pubitemid 47555336)
33. Crewe, H.K., Ellis, S.W., Lennard, M.S. & Tucker, G.T. Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes. Biochem. Pharmacol. 53, 171-178 (1997). (Pubitemid 27013472)
34. Desta, Z., Ward, B.A., Soukhova, N.V. & Flockhart, D.A. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J. Pharmacol. Exp. Ther. 310, 1062-1075 (2004). (Pubitemid 39108928)
35. Brauch, H., Mürdter, T.E., Eichelbaum, M. & Schwab, M. Pharmacogenomics of tamoxifen therapy. Clin. Chem. 55, 1770-1782 (2009).
36. Hoskins, J.M., Carey, L.A. & McLeod, H.L. CYP2D6 and tamoxifen: DNA matters in breast cancer. Nat. Rev. Cancer 9, 576-586 (2009).
37. Liu, Y.T., Hao, H.P., Liu, C.X., Wang, G.J. & Xie, H.G. Drugs as CYP3A probes, Inducers, And inhibitors. Drug Metab. Rev. 39, 699-721 (2007).
38. Sideras, K. et al. Coprescription of tamoxifen and medications that inhibit CYP2D6. J. Clin. Oncol. 28, 2768-2776 (2010).
39. Kelly, C.M. & Buzdar, A.U. Aromatase inhibitors alone or in sequence with tamoxifen - clinical evaluation of the BIG 1-98 trial. Expert Opin. Pharmacother. 11, 489-492 (2010).
40. Lash, T.L. et al. Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifen. Acta Oncol. 49, 305-312 (2010).
41. Sun, D. et al. Glucuronidation of active tamoxifen metabolites by the human UDP glucuronosyltransferases. Drug Metab. Dispos. 35, 2006-2014 (2007). (Pubitemid 350010805)
42. Gauthier, S., Mailhot, J. & Labrie, F. New Highly Stereoselective Synthesis of (Z)-4-Hydroxytamoxifen and (Z)-4-Hydroxytoremifene via McMurry Reaction. J. Org. Chem. 61, 3890-3893 (1996). (Pubitemid 26201038)
43. Kaku, T., Ogura, K., Nishiyama, T., Ohnuma, T., Muro, K. & Hiratsuka, A. Quaternary ammonium-linked glucuronidation of tamoxifen by human liver microsomes and UDP-glucuronosyltransferase 1A4. Biochem. Pharmacol. 67, 2093-2102 (2004). (Pubitemid 38595490)
44. Heinkele, G., Schänzle, G., Mürdter, T.E. Synthesis of [2H3]-dextromethorphan and its major urinary metabolites [2H3]-dextrorphan and [2H3]- dextrorphan ß-glucuronide. J. Labelled Comp. Radiopharm. 45, 1153-1158 (2002).
45. Burk, O. et al. Molecular mechanisms of polymorphic CYP3A7 expression in adult human liver and intestine. J. Biol. Chem. 277, 24280-24288 (2002). (Pubitemid 34951946)
46. Zanger, U.M., Raimundo, S. & Eichelbaum, M. Cytochrome P450 2D6: overview and update on pharmacology, Genetics, Biochemistry. Naunyn Schmiedebergs Arch. Pharmacol. 369, 23-37 (2004). (Pubitemid 38161221)